Guidelines for control of meningococcal disease. Laboratory Centre for Disease Control. Canadian Consensus Conference on Meningococcal Disease.
D000293:Adolescent; D000328:Adult; D001428:Bacterial Vaccines; D002170:Canada; D002443:Ceftriaxone / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D002939:Ciprofloxacin / Q000009:adverse effects / Q000627:therapeutic use; D003140:Communicable Disease Control / Q000592:standards*; D005260:Female; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D008589:Meningococcal Infections / Q000188:drug therapy / Q000453:epidemiology / Q000517:prevention & control*; D022401:Meningococcal Vaccines; D011247:Pregnancy; D011634:Public Health; D012293:Rifampin / Q000009:adverse effects / Q000627:therapeutic use*; D014611:Vaccination
D001428:Bacterial Vaccines; D022401:Meningococcal Vaccines; D002939:Ciprofloxacin; D002443:Ceftriaxone; D012293:Rifampin